仙灵骨葆胶囊致不良反应185例文献分析
x

请在关注微信后,向客服人员索取文件

篇名: 仙灵骨葆胶囊致不良反应185例文献分析
TITLE:
摘要: 目的:探讨仙灵骨葆胶囊致不良反应(ADR)的规律及特点,为临床合理用药提供参考。方法:检索2007年1月-2016年10月中国期刊全文数据库(CJFD)、中国生物医学文献数据库(CBM)、万方数据库、维普数据库(VIP)报道的仙灵骨葆胶囊致ADR病例,并就收集到的185例ADR相关信息进行统计和分析。结果:185例患者中,原患疾病主要为骨质疏松症的有63例(34.05%);联合用药ADR发生率(70.81%)显著高于单用药(29.19%);ADR多发生在用药后90 d内(67.03%),临床表现主要以消化系统损害较多(82.68%); 大部分患者(61.62%)未予处理或经对症治疗或停药后缓解症状。结论:临床应加强对仙灵骨葆胶囊ADR的监测,尤其应重视其在肝功能方面的ADR,以促进合理用药,保证用药安全。
ABSTRACT: OBJECTIVE: To investigate the regularity and characteristics of adverse drug reactions (ADR) induced by Xianling gubao capsule, and to provide reference for rational drug use in the clinic. METHODS: ADR induced by Xianling gubao capsule were retrieved from CJFD, CBM, Wanfang database, VIP during Jan. 2007-Oct. 2016. The related information of 185 ADR cases were statistically analyzed. RESULTS: Among 185 patients, primary disease was mainly osteoporosis (63 cases, 34.05%). The incidence of ADR induced by drug combination (70.81%) was higher than single drug (29.19%). ADR mostly occurred within 90 d after medication (67.03%). Main clinical manifestation was digestive system damage (82.68%). Most patients (61.62%) did not need treatment, symptomatic treatment or drug withdrawal to relieve ADR symptoms. CONCLUSIONS: The monitoring for ADR induced by Xianling gubao capsule should be strengthened in clinic,especially for ADR of liver fuction,soas to promote rational drug use.
期刊: 2017年第28卷第27期
作者: 杜倩,王哲,运乃茹,黄宇虹,徐强,王保和
AUTHORS: DU Qian,WANG Zhe,YUN Nairu,HUANG Yuhong,XU Qiang,WANG Baohe
关键字: 仙灵骨葆胶囊;不良反应;文献分析;合理用药
KEYWORDS: Xianling gubao capsule; ADR; Literature analysis; Rational drug use
阅读数: 389 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!